General contact

Main switchboard

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST


Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999


Investor Relations

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Diseases of the developing world

More than one billion people - one-sixth of the world's population - are affected by neglected diseases. There is an urgent need to develop better, more affordable vaccines and drugs for diseases that are devastating in developing countries.

Novartis is committed to researching treatments and vaccines for diseases of the developing world through two specialized institutes.

Our efforts focus on major infectious diseases including malaria, TB, dengue and infectious diarrhea.

NITD is a collaboration between Novartis and the Singapore Economic Development Board, with more than 100 international scientists based in Singapore. The institute researches novel treatments for major tropical diseases, and provides teaching and training for graduate students and post-doctoral fellows, building capacity to address medical challenges in the developing world. Medicines discovered by the institute will be made available at not-for-profit prices to patients who need them.

NVGH is dedicated to discovering vaccines for diseases that do not receive adequate attention, particularly diarrheal diseases that cause 2 million deaths every year. The institute collaborates with a number of organizations worldwide, including the Wellcome Trust, the Bill and Melinda Gates Foundation and the Global Alliance for Vaccines and Immunization. Access to and affordability of NVGH products is core to the institute's mission.

Applying novel research to diseases of the developing world

In collaboration with OneWorld Health, a US-based not-for-profit pharmaceutical company, NIBR is applying expertise from research targeting cystic fibrosis to tackle secretory diarrhea - a disease that kills more than 1.6 million children a year in developing countries.